NanoPhoria S

Using a two-level inhalable particle design, NanoPhoria is exploiting the unique connection between the lungs and heart to deliver peptides and nucleic aci...

Ten young European biotechs are heading into 2026 with the kind of momentum that can quickly turn promising science into defining data: first clinical entries, platform-to-pipeline transitions, and funding rounds large enough to accelerate execution. Some

Industry leaders, executives and investors forecast that M&A will accelerate in 2026, driven by patent cliff urgency. However, capital is becoming more selective, flowing towards proven assets, novel biology and innovative financing structures.